Skip to main content

Biosimilars

Meeting Highlights

Biosimilars, ASCO Highlights

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

Biosimilars

Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC

Biosimilars

Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL

Biosimilars

Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma

Biosimilars

Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics

Biosimilars

Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors

Biosimilars

Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment

Biosimilars

Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers

Biosimilars

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell NHL

Biosimilars

Scaled Integration of FDA-Approved Biosimilars

1
2
3
4
5

Page 2 of 8
Results 11 - 20 of 73